Giant cell tumors of bone (GCTB) are semi-malignant tumors associated with extensive osteolytic defects and massive bone destructions. They display a locally aggressive behavior and a very high recurrence rate. Recently, a single mutation has been identified in GCTB affecting the H3F3A gene coding for the histone variant H3.3 (H3.3-G34W). The aim of this study was to investigate whether H3.3-G34W is sufficient to drive tumorigenesis in GCTB. Initially, we confirmed the high frequency of this mutation in 94% of 84 analyzed tissue samples. Using a siRNA based approach we could selectively knockdown H3.3-G34W in primary neoplastic stromal cells isolated from tumor tissue (GCTSC). H3.3-G34W knockdown caused a significant inhibition of cell proliferation, migration and colony formation capacity in vitro. Xenotransplantation of GCTSCs onto the chorioallantoic membrane of fertilized chicken eggs further demonstrated a significant impact of H3.3-G34W knockdown on tumor engraftment and growth in vivo. Our data indicate that H3.3-G34W is sufficient to drive tumorigenesis in GCTB. Apart from the application of H3.3-G34W screening as diagnostic tool, our data suggest that H3.3-G4W represents a promising target for the development of new GCTB therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canlet.2019.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Giant cell inflammatory reaction to hemostatic cellulose matrix mimicking renal cell carcinoma recurrence.
Minerva Urol Nephrol
January 2025
Department of Urology, University of Verona, A.O.U.I. Verona, Italy.
Role of MRI and surgical excision in long-standing diffuse-type GCTTS of the flexor tendon sheath.
Radiol Case Rep
March 2025
First Orthopaedic Department, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece.
Diffuse-type giant cell tumor of the tendon sheath (GCTTS) is a rare, benign, yet locally aggressive soft tissue tumor commonly affecting the hand. This case report presents a 55-year-old male with a 5-year history of GCTTS in the flexor tendon sheath of the long finger. MRI played a critical role in both diagnosis and surgical planning, revealing key features such as the tumor's 10 cm length, hemosiderin deposition, and blooming artifacts.
View Article and Find Full Text PDFSuccessful Surgical Management of Giant, Shamblin III Carotid Body Tumor (CBT) on a Male With 5 Years of Follow-Up: Case Report and Literature Review on Giant CBT.
Vasc Endovascular Surg
January 2025
Department of Surgery, Section of Vascular Surgery and Endovascular Therapy, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Background: Carotid body tumor (CBT) is a rare neoplasm that arises from the chemoreceptor cells located at the carotid bifurcation. Giant CBTs are extremely rare, with only 16 cases reported to date.
Case Summary: A 63-year-old male with an unremarkable medical history presented with a right-sided, giant, Shamblin III CBT.
Study protocol for a single-centre non-inferior double-blinded randomised controlled trial in China comparing the efficacy and safety of high-frequency irreversible electroporation with transurethral resection of the prostate in treating lower urinary tract symptoms and benign prostatic obstruction (the GIANT trial).
BMJ Open
January 2025
Department of Urology, Tongji University School of Medicine, Shanghai, China
Introduction: Transurethral resection of the prostate (TURP) is the gold standard surgical treatment to lower urinary tract symptoms and benign prostatic obstruction (LUTS/BPO). Although it has been proven to have substantial efficacy in improving functional outcomes, it has shown a high incidence of complications, including transurethral resection syndrome, massive bleeding, urinary incontinence and sexual dysfunction. High-frequency irreversible electroporation (H-FIRE) is a novel non-thermal ablation technique that delivers pulsed high-voltage but low-energy electric current to the cell membrane, thereby leading to cell death.
View Article and Find Full Text PDFThe Effect of Denosumab on Pain and Radiological Improvement in Giant Cell Tumours of the Spine in the Acute Setting.
Global Spine J
January 2025
Department of Spinal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Study Design: Retrospective Cohort Study.
Objectives: The current recommended treatment for Giant Cell Tumour (GCT) of the spine is en bloc excision. Denosumab is a monoclonal antibody reducing osteoclast activity that shows promising results when used as a neo - adjuvant treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!